Usmani, S. Z., Facon, T., Hungria, V., Bahlis, N. J. J., Venner, C. P., Braunstein, M. J., Pour, L., Marti, J., Basu, S., Cohen, Y. C., Suzuki, K., Hulin, C., Grosicki, S., Beksac, M., Maiolino, A., Stanziola, J., Lopez-Masi, L., Loi, M., Rowe, M., Zweegman, S. (2026). Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM): Final analysis of transplant-ineligible (TIE) pts in the phase 3 CEPHEUS study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.7513